Sanofi

SanofiSanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

www.sanofi.com

Filters
List of articles in category Sanofi
Title Published Date
Foundation S: Sanofi's new philanthropic spearhead 04 May 2022
Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board 12 April 2022
Sanofi unveils new corporate brand and logo - unites the company under one purpose and a single identity 07 February 2022
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines 21 January 2022
Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline 26 November 2021
Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations 11 October 2021
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate 29 September 2021
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development 05 August 2021
Sanofi launches dedicated vaccines mRNA Center of Excellence 29 June 2021
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial 17 May 2021
Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands 26 April 2021
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate 19 March 2021
Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands 23 February 2021
Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs 27 January 2021
Sanofi offers to acquire Kiadis for €308 million 05 November 2020
Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine 28 October 2020
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies 16 October 2020
Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union 18 September 2020
Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate 03 September 2020
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. 01 September 2020